» Articles » PMID: 18201145

Androgen Deprivation Therapy for Prostate Cancer

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2008 Jan 19
PMID 18201145
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Androgen deprivation continues to play a crucial role in the treatment of advanced and metastatic prostate cancer. In the 65 years since its use was first described, urologists and medical oncologists have developed new and innovative ways to manipulate the hypothalamic-pituitary-gonadal axis with the goal of alleviating symptoms and prolonging the life of men with prostate cancer. Despite the successes that androgen deprivation therapy has brought, each method and regimen possesses unique benefits and burdens, of which the clinician and patient must be cognizant. This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgen deprivation therapy.

Citing Articles

Mineralocorticoid receptor signaling inhibits bladder cancer progression.

Nagata Y, Goto T, Teramoto Y, Matsukawa T, Fujimoto N, Miyamoto H Am J Cancer Res. 2024; 14(2):696-708.

PMID: 38455412 PMC: 10915320.


TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.

Zhang Y, Huang Z, Li K, Xie G, Feng Y, Wang Z J Exp Clin Cancer Res. 2024; 43(1):16.

PMID: 38200609 PMC: 10782585. DOI: 10.1186/s13046-023-02920-w.


Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy.

Tatenuma T, Miyamoto H Drug Des Devel Ther. 2023; 17:2325-2333.

PMID: 37559910 PMC: 10408655. DOI: 10.2147/DDDT.S373546.


Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis.

Chen J, Yuan Y, Fang M, Zhu Y, Sun X, Lou Y Front Endocrinol (Lausanne). 2023; 13:1074540.

PMID: 36733800 PMC: 9887024. DOI: 10.3389/fendo.2022.1074540.


Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study.

Angulo J, Ciria Santos J, Gomez-Caamano A, Poza de Celis R, Gonzalez Sala J, Garcia Garzon J World J Urol. 2022; 40(10):2459-2466.

PMID: 36057895 PMC: 9512882. DOI: 10.1007/s00345-022-04108-x.